News Sentiment

SGP sentiment intelligence

SpyGlass Pharma, Inc. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 58 Balanced news tone 51 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 22.52 Week of 10 Jul 2026
Weighted tone 58/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

82/100 classification confidence.

Company focus 42

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend inactive

+17.6% over one week, +22.1% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Neutral

Top Spyglass Pharma (SGP) Competitors 2026

Market Reaction

Price moving ahead of tone

68/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 82/100 classification
One-week reaction 17.6% Price confirming higher
Trend fit Trend inactive 22.1% over four weeks
Fair value -3.2% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 19
Neutral 31
Negative 1

Relevance

Why the article matched

Direct first
Direct company coverage 42
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 6
www.marketscreener.com 6
TradingView 6
MarketBeat 5
Investing.com 4
Stock Titan 3
GlobeNewswire 3
Orange County Business Journal 2

Event Lens

What the news is about

Classified themes
Market update 30
Earnings 14
Deals and strategy 4
Balance sheet 1
Regulatory and legal 1
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 51
www.marketscreener.com Direct company coverage

SpyGlass Pharma, Inc.(NasdaqGS:SGP) added to Russell Microcap Growth Benchmark Index

SpyGlass Pharma, Inc. (NasdaqGS:SGP) has been added to the Russell Microcap Growth Benchmark Index. This inclusion follows several other additions for the company to various Russell indices, including the Russell 2000, Russell Microcap Value, and Russell 3000E. SpyGlass Pharma is

Tone
Positive 70/100
Event
Market update
Published
29 Jun 2026 18:39
Source
www.marketscreener.com
www.marketscreener.com Direct company coverage

SpyGlass Pharma, Inc.(NasdaqGS: SGP) added to Russell 2000 Index

SpyGlass Pharma, Inc. (NasdaqGS: SGP) has been added to the Russell 2000 Index. This inclusion follows several other recent index additions, including the S&P Global BMI Index and the S&P TMI Index, highlighting the company's growing recognition in the financial markets. The opht

Tone
Positive 71/100
Event
Market update
Published
29 Jun 2026 17:57
Source
www.marketscreener.com
www.marketscreener.com Direct company coverage

SpyGlass Pharma, Inc.(NasdaqGS: SGP) added to Russell 2000 Value Benchmark

SpyGlass Pharma, Inc. (NasdaqGS:SGP) has been added to the Russell 2000 Value Benchmark, according to an announcement published on MarketScreener. The company specializes in ophthalmic drug delivery, with its flagship product being the SpyGlass Drug Delivery Platform designed to

Tone
Positive 71/100
Event
Market update
Published
29 Jun 2026 16:12
Source
www.marketscreener.com
www.marketscreener.com Direct company coverage

SpyGlass Pharma, Inc.(NasdaqGS: SGP) added to Russell 2000 Growth Benchmark

SpyGlass Pharma, Inc. (NasdaqGS: SGP) has been included in the Russell 2000 Growth Benchmark. This news follows several other recent updates for the company, including presentations at major healthcare conferences and its addition to the S&P Global BMI Index and S&P TMI Index, hi

Tone
Positive 70/100
Event
Market update
Published
29 Jun 2026 11:12
Source
www.marketscreener.com
TradingView Direct company coverage

Price to earnings forward of SpyGlass Pharma, Inc. – NASDAQ:SGP

This article provides limited financial information for SpyGlass Pharma, Inc. (NASDAQ: SGP), specifically mentioning its "Price to earnings forward." The full data for this metric is not displayed in the provided text. The page appears to be a financial data portal from TradingVi

Tone
Neutral 50/100
Event
Earnings
Published
29 Jun 2026 07:41
Source
TradingView
TradingView Direct company coverage

SpyGlass Pharma, Inc. Actuals & Estimates (NASDAQ:SGP)

This article provides key financial data and analyst estimates for SpyGlass Pharma, Inc. (NASDAQ: SGP). It covers the company's current stock price, historical performance, future price forecasts from analysts, and recent financial results including earnings and revenue. The info

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 20:40
Source
TradingView
TradingView Direct company coverage

Price to sales forward of SpyGlass Pharma, Inc. – NASDAQ:SGP

This article focuses on the "Price to sales forward" financial metric for SpyGlass Pharma, Inc. (NASDAQ: SGP). It appears to be a stub or a section of a larger financial data page, indicating that this specific data point is provided by TradingView, with underlying data from ICE

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 18:40
Source
TradingView
TradingView Direct company coverage

Enterprise value to revenue forward of SpyGlass Pharma, Inc. – NASDAQ:SGP

This article provides financial data for SpyGlass Pharma, Inc. (NASDAQ: SGP), specifically focusing on its enterprise value to revenue forward. The content is presented within the context of a financial platform, indicating a focus on market analytics and company performance metr

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 18:39
Source
TradingView
TradingView Direct company coverage

Price to book forward of SpyGlass Pharma, Inc. – NASDAQ:SGP

This article provides the "Price to book forward" for SpyGlass Pharma, Inc. (NASDAQ: SGP). It appears to be a financial data snippet from TradingView, indicating no trades and a market closed status, presenting the fundamental value for the specified period.

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 09:39
Source
TradingView
MarketBeat Direct company coverage

Spyglass Pharma (SGP) Short Interest & Short Float | Updated Jun 2026 $SGP

As of June 15, 2026, Spyglass Pharma (SGP) had a short interest of 1.01 million shares, representing 3.03% of its public float, an 11.57% decrease from the previous report. The short interest ratio is 14.3 days to cover. This indicates that while still considered high, investor s

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 03:40
Source
MarketBeat
www.marketscreener.com Direct company coverage

SpyGlass Pharma, Inc.(NasdaqGS: SGP) added to S&P Global BMI Index

SpyGlass Pharma, Inc. (NasdaqGS: SGP) has been included in the S&P Global BMI Index. The company, which specializes in ophthalmic drug delivery solutions, was added to the index as announced on June 21, 2026, at 10:30 PM EDT. This inclusion highlights SpyGlass Pharma's growing pr

Tone
Positive 76/100
Event
Market update
Published
22 Jun 2026 02:41
Source
www.marketscreener.com
Pluang Direct company coverage

SpyGlass Pharma appoints Shannon Treviño as general counsel to support Phase 3 trials and commercialization plans.

SpyGlass Pharma has appointed Shannon Treviño as its new general counsel, leveraging her extensive legal and leadership experience, including guiding Inari Medical through a $4.9 billion acquisition. Her appointment is strategic as SpyGlass advances its BIM-IOL System through Pha

Tone
Positive 72/100
Event
Deals and strategy
Published
16 Jun 2026 11:40
Source
Pluang
Stock Titan Direct company coverage

GC who helped guide Inari through $4.9B Stryker acquisition joins SpyGlass

SpyGlass Pharma (Nasdaq: SGP) has appointed Shannon Treviño as its new General Counsel. Treviño previously served as General Counsel at Inari Medical, where she played a key role in its $4.9 billion acquisition by Stryker, and brings extensive experience in corporate, M&A, and se

Tone
Positive 73/100
Event
Deals and strategy
Published
16 Jun 2026 00:09
Source
Stock Titan
Orange County Business Journal Direct company coverage

SpyGlass Taps Shannon Treviño as General Counsel

SpyGlass Pharma Inc., an Aliso Viejo-based biopharmaceutical company, has appointed Shannon Treviño as its new General Counsel. Treviño previously served as general counsel and corporate secretary at Inari Medical, which was acquired by Stryker Corp. for $4.9 billion. This appoin

Tone
Positive 66/100
Event
Market update
Published
15 Jun 2026 17:09
Source
Orange County Business Journal
Investing.com Direct company coverage

SpyGlass Pharma appoints Shannon Treviño as general counsel

SpyGlass Pharma has appointed Shannon Treviño as its new general counsel. Treviño brings extensive experience from Inari Medical, where she oversaw legal and compliance, including a $4.9 billion acquisition by Stryker, and her prior work advising early and growth-stage companies.

Tone
Positive 60/100
Event
Deals and strategy
Published
15 Jun 2026 13:10
Source
Investing.com
www.marketscreener.com Direct company coverage

SpyGlass Pharma, Inc. Announces Appointment of Shannon Treviño to General Counsel

SpyGlass Pharma, Inc. has announced the appointment of Shannon Treviño as its new General Counsel. Ms. Treviño brings extensive experience in corporate, M&A, and securities law within the healthcare sector, having previously served as General Counsel and Corporate Secretary at In

Tone
Positive 72/100
Event
Market update
Published
15 Jun 2026 13:09
Source
www.marketscreener.com
Investing.com Canada Direct company coverage

SpyGlass Pharma appoints Shannon Treviño as general counsel By Investing.com

SpyGlass Pharma has appointed Shannon Treviño as its new general counsel. Treviño brings extensive experience, having previously served as General Counsel and Corporate Secretary at Inari Medical, where she managed legal and compliance during a major acquisition. SpyGlass Pharma,

Tone
Positive 64/100
Event
Deals and strategy
Published
15 Jun 2026 12:09
Source
Investing.com Canada
VisionMonday.com Direct company coverage

SpyGlass Pharma Appoints Mike Pinder as Vice President, Marketing

SpyGlass Pharma has appointed Mike Pinder as Vice President, Marketing, effective May 18, 2026. Pinder brings over 20 years of ophthalmology commercial launch experience and will be responsible for building and leading the company's marketing function as it advances its Bimatopro

Tone
Positive 74/100
Event
Market update
Published
03 Jun 2026 04:09
Source
VisionMonday.com
Investing.com South Africa Direct company coverage

SpyGlass Pharma appoints Mike Pinder as VP of marketing By Investing.com

SpyGlass Pharma announced the appointment of Mike Pinder as VP of marketing. Pinder brings significant ophthalmology commercial launch experience and will lead the marketing function as the company advances its Bimatoprost Drug Pad-IOL System through Phase 3 clinical trials. This

Tone
Neutral 50/100
Event
Market update
Published
02 Jun 2026 18:39
Source
Investing.com South Africa
Investing.com Direct company coverage

SpyGlass Pharma appoints Mike Pinder as VP of marketing

SpyGlass Pharma has appointed Mike Pinder as Vice President of Marketing. Pinder brings over 20 years of ophthalmology commercial launch experience and will lead the marketing function as the company advances its Bimatoprost Drug Pad-IOL System through Phase 3 clinical trials. Th

Tone
Neutral 50/100
Event
Market update
Published
02 Jun 2026 12:39
Source
Investing.com
Stock Titan Direct company coverage

Drop-free glaucoma BIM-IOL system taps veteran marketer

SpyGlass Pharma (Nasdaq: SGP) has appointed Mike Pinder as Vice President, Marketing, to lead commercialization efforts for its Bimatoprost Drug Pad-IOL System (BIM-IOL System). Pinder brings over 20 years of ophthalmology marketing experience from companies like Astellas, Novart

Tone
Positive 72/100
Event
Market update
Published
02 Jun 2026 11:39
Source
Stock Titan
Sahm Direct company coverage

SpyGlass Pharma to Participate in Upcoming Investor Conferences

SpyGlass Pharma, Inc. (Nasdaq: SGP) announced its participation in three upcoming investor conferences in May and June 2026: the Stifel 2026 Virtual Ophthalmology Forum, the Jefferies Global Healthcare Conference, and the Goldman Sachs 47th Annual Global Healthcare Conference. Ex

Tone
Positive 66/100
Event
Market update
Published
26 May 2026 17:39
Source
Sahm
Stock Titan Direct company coverage

SpyGlass Pharma execs set for three June healthcare investor events

SpyGlass Pharma (Nasdaq: SGP) announced its executive management will participate in three upcoming investor conferences focused on healthcare and ophthalmology in May and June 2026. These events include the Stifel 2026 Virtual Ophthalmology Forum, the Jefferies Global Healthcare

Tone
Positive 64/100
Event
Market update
Published
21 May 2026 11:59
Source
Stock Titan
Orange County Business Journal Direct company coverage

SpyGlass Secures Billing Code for IOL Platform

SpyGlass Pharma Inc. has secured a new add-on Category III CPT Code for its intraocular lens (IOL) platform, which delivers glaucoma medication for up to three years. The Aliso Viejo-based company is currently in Phase 3 trials and aims for FDA submission by 2028 and commercial l

Tone
Neutral 50/100
Event
Market update
Published
19 May 2026 23:38
Source
Orange County Business Journal
Eyes On Eyecare Direct company coverage

SpyGlass Pharma: New add-on CPT code supports BIM-IOL System

The American Medical Association has approved a new add-on Category III CPT code for intraocular lens prosthesis-mounted drug-eluting implants, supporting SpyGlass Pharma's investigational Bimatoprost Drug Pad-IOL (BIM-IOL) System. This system aims to deliver bimatoprost for thre

Tone
Positive 74/100
Event
Regulatory and legal
Published
19 May 2026 18:38
Source
Eyes On Eyecare
Market source Direct company coverage

SpyGlass Pharma Announces New Add-on Category III CPT Code for Its Innovative BIM-IOL System

SpyGlass Pharma announced that the AMA's CPT Editorial Panel approved a new add-on Category III CPT code for its Bimatoprost Drug Pad-IOL System (BIM-IOL System). This code will support reimbursement for surgeons using the device in conjunction with cataract surgery, aiming to im

Tone
Positive 73/100
Event
Market update
Published
18 May 2026 20:10
Source
Market source